Evidence-based Therapy and Problem of Glioblastoma

Abstract

  Prolonged survival in glioblastoma was achieved by supplementing temozolomide with radiotherapy and through adjuvant chemotherapy with temozolomide. Numerous trials have aimed to improve the survival time in glioblastoma, but no further advancements with chemotherapy have yet been achieved. In this review, we focus on standard therapy for newly diagnosed glioblastoma, comprising maximal resection followed by radiotherapy supplemented with temozolomide. Furthermore, we discuss the therapeutic efficacy of 5-aminolevulinic acid, carmustine wafers, bevacizumab, and tumor treating fields (TTF). In addition, we introduced the current social problems associated with glioblastoma treatment and its prospects for future research.